Previous close | 89.84 |
Open | 89.34 |
Bid | 0.00 x 1300 |
Ask | 0.00 x 1000 |
Day's range | 89.27 - 89.99 |
52-week range | 74.09 - 94.26 |
Volume | |
Avg. volume | 2,004,071 |
Market cap | 193.093B |
Beta (5Y monthly) | 0.49 |
PE ratio (TTM) | 9.23 |
EPS (TTM) | 9.70 |
Earnings date | N/A |
Forward dividend & yield | 3.33 (3.70%) |
Ex-dividend date | 08 Mar 2022 |
1y target est | 104.25 |
The Swiss drugmaker recently shared promising phase 3 clinical trial results for this rare-disease drug.
Novartis' (NVS) generic unit Sandoz is set to acquire rights to the antifungal product Mycamine from Astellas.
Sandoz plans to acquire worldwide product rights for Mycamine® (micafungin sodium) from AstellasAcquiring leading global echinocandin, one of three major antifungal classes, will significantly reinforce Sandoz hospital offering and leading anti-infectives portfolioAddition of Mycamine® will support Sandoz global program to combat antimicrobial resistance (AMR) by targeted use of most appropriate therapies Basel, January 24, 2023 – Sandoz, the global leader in off-patent (generic and biosimilar)